# Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

> **NCT01430351** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 144 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Supratentorial Glioblastoma

## Interventions

- **DRUG:** Mefloquine
- **DRUG:** Memantine Hydrochloride
- **DRUG:** Metformin Hydrochloride
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01430351
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09-14
- **Primary completion:** 2025-02-02
- **Final completion:** 2025-02-02
- **Target enrollment:** 144 (ACTUAL)
- **Why stopped:** \<75 % participant accrual
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430351, "Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01430351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*